Marksans Pharma Ltd. - Research Center
524404 MARKSANS Group (A) BSE data
Results
Statement
More
Mar ' 23 |
Mar ' 22 |
Mar ' 21 |
Mar ' 20 |
Mar ' 19 |
Equity share capital
45.32 |
40.93 |
40.93 |
40.93 |
40.93 |
Share application money
Preference share capital
Reserves & surplus
1,066.01 |
743.74 |
558.79 |
464.69 |
429.64 |
Secured loans
Unsecured loans
Total
1,111.32 |
789.67 |
599.72 |
505.63 |
557.90 |
Gross block
264.65 |
234.33 |
224.19 |
196.31 |
173.02 |
Less : revaluation reserve
Less : accumulated depreciation
120.71 |
98.81 |
95.11 |
81.13 |
70.41 |
Net block
143.94 |
135.51 |
129.09 |
115.18 |
102.61 |
Capital work-in-progress
Investments
266.29 |
236.51 |
236.07 |
236.07 |
236.07 |
Current assets, loans & advances
930.72 |
593.59 |
353.40 |
248.52 |
273.30 |
Less : current liabilities & provisions
233.54 |
175.94 |
118.84 |
94.15 |
54.09 |
Total net current assets
697.18 |
417.65 |
234.56 |
154.37 |
219.21 |
Miscellaneous expenses not written
Total
1,111.32 |
789.67 |
599.72 |
505.63 |
557.90 |
Book value of unquoted investments
265.75 |
236.07 |
236.07 |
236.07 |
236.07 |
Market value of quoted investments
Contingent liabilities
9.31 |
114.36 |
115.10 |
140.38 |
30.40 |
Number of equity sharesoutstanding (Lacs)
4531.64 |
4093.14 |
4093.14 |
4093.14 |
4093.14 |